ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its internationally patented Coblation (R) technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS (R) line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.

HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation. The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology.

BioVentrix, Inc. engages in development of medical devices. It offers Less Invasive Ventricular Enhancement, or the LIVE therapy, which uses the Revivent TC transcatheter ventricular enhancement system to exclude scar tissue on the left ventricle that has occurred from a heart attack. The company was founded by Arthur A. Bertolero and Lon S. Annest in 2003 and is headquartered in San Ramon, CA.

Nimbus Medical, Inc., a subsidiary of Abbott Laboratories, is a company headquartered in Rancho Cordova, CA, focused on commercial physical and biological research. The firm was acquired by Thoratec Cardiosystems, Inc. on December 27, 1996 for $5 million.

ValveXchange, Inc. develops two-part bioprosthetic tissue valves that resolve the compromises between conventional mechanical and tissue heart valves. It offers Vitality exchangeable heart valve systems; Vitality exchangeable tissue valves; valve delivery and exchange systems; transapical implants and exchanges; and apical introducers. ValveXchange is based in Aurora, Colorado.

FineHeart SA manufactures medical devices for cardiovascular space. It offers wirelessly powered and fully-implantable mechanical circulatory support device. The company was founded by St��phane Garrigue and Philippe Ritter on January 13, 2010 and is headquartered in Pessac, France.

Eucardia develops a unique and innovative medical device: the Heart Damper. The Heart Damper is a minimally invasive implantable cardiac device intended to provide a simple, quick and cost effective solution for patients affected by advanced heart failure, improving duration and quality of life, and reducing healthcare costs for their assistance.

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify™ (perflubutane polymer microspheres) injectible suspension, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for U.S. approval. Imagify was created using Acusphere’s proprietary porous microparticle technology, which was also used to create three other drugs which have begun clinical development – AI-525 for acute pain, AI-850 for oncology and AI-128 for asthma. AI-525 and AI-850 were sold to Cephalon in transactions totaling $31 million. AI-128 was developed in collaboration with Elan, who contributed $7.5 million to the program. Acusphere’s technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.

Guangdong Cardiovascular Institute is a private company headquartered in Guangdong, China, that provides healthcare and surgical services.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

Nordischer Maschinenbau Rud. Baader GmbH & Co. KG manufactures food processing machinery. It offers fish and poultry processing equipment, separators and sizing equipment. The firm also offers maintenance, inspection and training services. The company was founded by Rudolph M. J. Baader in 1919 and is headquartered in Lübeck, Germany.

Dong-A Pharmaceutical Co., Ltd., a subsidiary of Dong-A Socio Holdings Co., Ltd., is a company headquartered in Seoul, the South Korea, that manufactures drug products.

Sorin CRM SAS designs and manufactures implantable pacemakers and defibrillators. It offers ICDs, leads, holter equipment, and electrophysiology catheters. The company was founded on July 25, 1977 and is headquartered in Clamart, France.

Hangzhou Shengshi Technology Co., Ltd., established on 2017-04-18, Business scope includes IoT information technology,information Technology,Technical consulting for electronic technology,technology development,technology transfer,Technical Services;the first sort,second category,Production of Class III Medical Devices(limited software),the first sort,second category,Sales of Class III Medical Devices;Electronic Component,Sales of computer hardware and software;Business Management Consulting,Business Consulting(In addition to commodity intermediary),Enterprise Marketing Planning,Conference Services,Exhibition display service;Import and export of goods and technology(law,Except for items prohibited by administrative regulations,law,Projects that are restricted by administrative regulations can only be operated after obtaining a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.